From Solid-State Control to Predictive Precision: Building a Deployable Ecosystem for Psychedelic Therapeutics.
ACS Med Chem Lett January 12, 2026 DOI: 10.1021/acsmedchemlett.5c00782 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Patent application analysis Peer reviewed |
|---|---|
| Key points | Psychedelic drug development is expanding toward deployable therapeutic systems that address manufacturing and patient-response prediction bottlenecks. |
Abstract
Two recent patent applications illustrate how psychedelic drug development is expanding beyond molecules and experiences toward deployable therapeutic systems. One focuses on solid-state optimization of a lysergamide analogue to ensure manufacturability and stability, while the other applies machine-learning-driven neurophysiological biomarkers to predict patient response. Together, they address complementary translational bottlenecks in psychedelic medicine.